Newsbenzinga
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
· Published
Article summary
MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.
An excerpt from the original article.
Comments —
Loading comments…